Background Genetic information has the potential to create a more personalised, prompt, early and accurate risk evaluation. The effect of these genetic variants on the serum biomarker levels ( phenotype) needs to be studied to assess their potential causal role in the pathogenesis of premature coronary artery disease (PCAD). Objectives were to determine the genotypic distribution of interleukin (IL) 18, tumour necrosis factor-α (TNFA), IL6 and IL10 single nucleotide polymorphisms (SNPs) in Pakistani PCAD cases and disease free controls and to study the effect of these gene polymorphisms on the serum cytokine levels (IL18, TNFA, IL6 and IL10) and cytokine imbalance (IL18:IL10 and TNFA:IL10). Material and methods The case-control study was carried out in National University of Sciences and Technology, Islamabad in collaboration with the Cardiovascular Genetics Institute, University College London, UK. Subjects (n=340) with >70% stenosis in at least a single major coronary artery on angiography were taken as PCAD cases along with 310 angiographically verified controls. ELISA was performed for measuring the concentrations of serum IL18, TNFA, IL6 and IL10. Genotyping was done using TAQMAN assay. Results The risk allele frequencies (RAFs) of rs1800795 (IL6) and rs187238 (IL18) cytokine gene promoter SNPs were significantly higher in the PCAD cases as compared with the controls. Serum IL18 and IL10 levels were significantly greater in the IL18 rs187238 GG genotype patients while serum IL18 and IL6 levels were significantly higher in patients having the IL6 rs1800795 CC genotype. IL18 SNP rs1946519 significantly altered the IL18, TNFA, IL6, IL18/IL10 and TNFA/IL10 ratio levels followed by TNFA SNP rs1800629 which significantly altered the serum levels of IL18, IL18:IL-0 and TNFA:IL10 ratios. Conclusions The association of the selected SNPs with differential serum cytokine levels especially the cytokine imbalance points towards their potential causal role in the immune inflammatory pathogenic pathway of PCAD.
INTRODUCTION
Premature coronary artery disease (PCAD) is characterised by >70% blockade in at least one major vessel as seen on coronary angiography in patients ≤45 years of age. 1 It is the leading cause of morbidity and mortality in young males and females. 2 PCAD occurs almost a decade earlier in the South Asian population as compared with the West. 3 It is estimated that by the year 2030 the cause of death in 23.3 million people annually will be CAD. 4 Cytokines are small proteins which are mainly released as a response of the host to disease or infection. A number of proinflammatory and antiinflammatory cytokines have been identified in the pathogenesis of PCAD and this inflammatory cascade has a role in maintaining a delicate balance between various factors that monitor the integrity of the vascular system. 5 Cytokine imbalance and its role in the acceleration of atherosclerosis has been highlighted. 6 Autieri 7 showed interleukin (IL) 18: IL10 can independently predict adverse events in patients with CAD. IL18:IL10 ratio has a vital role in formation of atherosclerotic arterial lesions. 8 Patients with CAD demonstrated higher values of tumour necrosis factor-α (TNFA):IL10 than the controls. 9 The effect of the cytokine genetic variants on the serum biomarker levels ( phenotype) needs to be studied to assess their potential causal role in the pathogenesis of PCAD. While certain studies have shown that the cytokine single nucleotide polymorphisms (SNPs) can lead to alteration in the inflammatory response in CAD 10 others have negated it. 11 Thus, a controversy still exists regarding the influence of these cytokine gene promoter polymorphisms on the serum cytokine levels particularly in the high risk Pakistani subjects. Hence, objectives were to determine the genotypic distribution of proinflammatory IL18 (rs1946519 and rs187238), TNFA (rs1800629), IL6 (rs1800795) and anti-inflammatory IL10 (rs1800871) gene promoter SNPs in patients with PCAD and disease free controls and to determine the differential serum cytokine levels (IL18, IL10, IL6, TNFA, IL18:IL10 and TNFA:IL10 ratios) with respect to the genotypic distribution of the selected SNPs in patients with PCAD and controls.
Material and methods
The case-control study was conducted in the Chemical Pathology department Army Medical College, National University of Sciences and Technology (NUST) Rawalpindi, Pakistan, in collaboration with Cardiovascular Genetics (CVG) Institute, University College London (UCL), London, UK after approval by the institutional ethical review committees. A total of 650 subjects aged ≤45 years who were stable and were due to undergo coronary angiography were consecutively recruited from Armed Forces Institute of Cardiology (AFIC) Rawalpindi. The participants had a recent history (<2 months) of an episode of left-sided chest pain and were advised angiography by consultant cardiologists after evaluation. All participants were citizens of Pakistan. The sampling technique was non-probability convenience sampling. Three hundred and forty subjects who displayed >70% stenosis in one coronary artery on angiography were categorised as patients with PCAD. Those patients who had a history of angina, previous myocardial infarction, infectious, autoimmune diseases, hyperlipidaemia (familial), heart disease by birth, arthritis, diabetes mellitus, expectance of life <12 months along with those not giving informed or written consent were not included in the study. Moreover, 310 age and sex matched controls who were declared to be disease free on angiography were recruited. Any subject with acute or chronic ailment or taking antiinflammatory drugs was not included in the control group. Expectant mothers or females taking contraceptives were excluded as well. General physical examination including detailed history and physical examination was done by a registered medical practitioner.
Ten-millilitre blood sample was taken from the median cubital vein. Six-millilitre blood was poured into a plain vacutainer tube to separate the serum. Serum total cholesterol levels by cholesterol oxidase method using Cholesterol-LQ kit (Pioneer Diagnostics) while GPO-POD colorimetric method was used to estimate serum triglyceride by TG kit by Linear Chemicals (Spain) on Selectra-E Chemistry Analyzer. Serum high density lipoprotein (HDL) was measured by direct enzymatic colourimetric method for quantifying cholesterol in HDL with HDL-Cholesterol kit (Linear Chemicals (Spain) on Selectra E Chemistry Analyzer. Serum low density lipoprotein was measured by Friedewald formula. Four ml whole blood was poured into EDTA tube to extract genomic DNA using Gentra Puregene Blood kit (Qiagen, USA). Serum IL18, TNFA, IL6 and IL10 levels were measured using monoclonal antibodies on ELISA (Invitrogen). The cytokine SNPs rs187238 (IL18), rs1800795 (IL6), rs1800629 (TNFA), rs1800871 (IL10) and rs1946519 (IL18) were genotyped using TAQMAN assays according to standard protocols and preformed primers. The reagent volumes for TAQMAN genotyping assays, per plate using TAQMAN buffer are shown in online supplementary table S1(a).
The PCR conditions for TAQMAN genotyping assays are summarised in online supplementary table S1(b).
Five cytokine gene promoter SNPs were selected from the meta-analyses 12 after a through literature search. 13 Details of SNPs selected for our study along with the respective references are shown in online supplementary table S2. [14] [15] [16] [17] Data analysis was done using standard SPSS software V.21 (SPSS, Chicago, Illinois, USA) and R V.3.0.3 (R Core Team, 2014). The allelic frequencies of all SNPs were checked for HardyWeinberg equilibrium (HWE) equation. Kolmogorov-Smirnov test of uniformity was applied on the data to assess its distribution. Mean±SD was calculated for continuous normally distributed (Gaussian distribution) variables. Continuous variables were compared among PCAD cases and controls using independent t-tests. Categorical variables between PCAD cases and controls were compared using χ 2 tests. Association between the gene polymorphisms and the serum cytokine levels were assessed by analysis of variance and post-hoc Tukey's test. A two-tailed p value <0.05 was taken as significant.
RESULTS
The patients of PCAD had mean±SD age of 42±3.80 years consisting of 329 males and 11 females. Demographic features are given in table 1.
Most of them were Punjabis 74% and only 26% were Pathans living in the Northern part of Pakistan. Body mass index, body weight, and systolic and diastolic blood pressure were significantly higher in patients with PCAD compared with controls ( p<0.05). The patients were mostly smokers with a positive family history of PCAD and hypertension (p<0.01). The genotypic distribution of the five cytokine SNPs namely IL18 rs187238, IL18 rs1946519, IL6 rs1800795, TNFA rs1800629 and IL10 r1800871 in patients with PCAD and controls along with their ORs and risk allele frequencies (RAFs) are shown in tables 2 and 3, respectively.
Among the cytokine SNPs TNFA rs1800629 and IL6 rs1800795 has the highest OR for the risk prediction of PCAD. All the cytokine SNPs complied with HWE. The RAFs of IL6 (rs1800795) and IL18 (rs187238) were significantly higher in the PCAD cases compared with the disease-free controls (p<0.05).
IL18 levels in serum were significantly greater in the IL18 rs187238 GG genotype subjects as compared with GC and CC genotypes ( p<0.05). Mean±SD values of serum IL18 levels were 277.1±4. 63, 257.9±7.57 and 217.8±7.68 pg/mL in GG, GC and CC genotypes, respectively. Interestingly serum IL10 level was also significantly greater in the GG homozygotes as compared with the GC and CC genotypes ( p<0.05). Mean±SD values of IL10 levels were 0.88±0.07, 0.85±0.12 and 0.81 ±0.12 in GG, GC and CC genotypes, respectively. Comparison of serum IL18 and IL10 cytokine levels with respect to the genotypic distribution of IL18 rs187238 SNP is shown in figure 1A .
Serum IL18, TNFA and serum IL6 levels were significantly higher in the IL18 rs1946519 GG genotype patients as compared with GT and TT genotypes ( p<0.05). Interestingly, the serum IL18:IL10 and TNFA:IL10 ratios were significantly figure 1C .
Serum IL18, IL18:IL10 and TNFA:IL10 ratios were significantly higher in the TNFA rs1800629 A-allele homozygotes as compared with GA and GG genotypes ( p<0.05) as shown in figure 1D . IL18 SNP rs1946519 had the maximum influence on the serum cytokine levels by significantly altering IL18, TNFA, IL6, IL18:IL10 and TNFA:IL10 ratio levels followed by TNFA SNP rs1800629 which significantly altered the serum levels of IL18, IL18:IL-0 and TNFA:IL10 ratios.
DISCUSSION
The risk allele of IL18 rs187238 and IL18 rs1946519 SNPs in our population was G based on OR of the allele for PCAD. This is in agreement with a study carried out on South Asian population by Kumar et al. 19 While some studies support the results of our study showing significant association of the IL18 rs187238 and IL18 rs1946519 SNPs with CAD 20 others have shown no such association. 21 A study done on Brazilian patients has also not shown any association of these SNPs with the cardiovascular risk factors. 22 The risk allele for IL6 rs1800795 our study was C. This is in agreement with another study carried out in highrisk Pakistani families where the minor allele C showed high prevalence in cases compared with controls. 10 While a strong association of the risk allele C was demonstrated with CAD in the Chinese 18 and Indians 23 no such association was seen in the Tunisians. 24 The Northwick Park Heart study on the other hand showed that the IL6 rs1800795 GC (heterozygotes) were significantly at a greater risk to develop CAD as compared with the CC homozygotes. 25 The RAF of TNFA rs1800629 did not vary significantly between the patients with PCAD and controls. The observation in our study conflicts with the results seen in a recent study carried out to see the association of TNFA rs1800629 SNP with familial CAD 26 and another study on Italian subjects 27 and Indians. 23 However, it agrees with some studies where there was no association between the TNFA rs1800629 SNP and CAD outcomes. 28 29 The risk allele in IL10 rs1800871 SNP was C in our study subjects however the risk allele in the Chinese Han population was identified as T for the IL10 rs1800871 SNP. 30 The RAF of IL10 rs1800871 was not raised significantly in the PCAD cases contrary to the observation of Afzal et al, 31 where the allele frequency of the protective allele T was significantly raised in the controls as compared with the cases. However, our results are in agreement with another study. 32 The cause of these inter-ethnic variations is not definitively known yet but the variable patterns of linkage disequilibrium resulting in 'tag SNPs' may differ by population strata. 12 Knowledge of these cytokine allele frequencies in our Pakistani subjects is essential because they may be a major contributing factor towards racial disparities with respect to the mortality and morbidity of low-grade inflammatory disease like PCAD. 33 Serum cytokines are in part a heritable trait. 34 The serum IL18 level was significantly raised in the GG genotype of the IL18 rs187238 SNP in patients with PCAD in our study as compared with the GC and CC genotypes. This observation is supported by another study which highlights the role of IL18 rs187238 SNP in variable expression of IL18. 35 Contrary to this it was reported in a previous study that IL18 levels were not influenced by the IL18 rs187238 genotypes. 36 Interestingly, serum IL10 was raised significantly in the risk allele homozygotes GG suggesting that the IL18 rs187238 G allele probably has an effect on the enhancers regulating the transcription of the IL10 gene promoter region leading to the increase in the anti-inflammatory cytokine production to counter the inflammatory response. The IL18 rs1946519 SNP GG genotype was significantly associated with higher proinflammatory cytokine levels (IL18, TNFA and IL6) and cytokine imbalance. This cytokine imbalance and greater susceptibility to the disease is probably because of the simultaneous action of the IL18 rs1946519 gene variant on the transcription regulation factors of the proinflammatory and anti-inflammatory cytokines mainly by promoting binding of the nuclear factors to transcription regulatory sites of these cytokines leading to variable mRNA expression. 37 The IL10 serum levels were not significantly different in the risk allele carriers of the IL10 rs1800871 SNP as compared with the non-carriers in our study. On the contrary, a study shows that IL10 levels are influenced by IL10 gene variants including rs1800871 SNP. 38 This is probably because the IL10 gene 5 0 -flanking sequence has three SNPs upstream from the transcriptional start site, at positions -1082 (G/A: rs1800896), -819 (C/T) and -592 (C/A: rs1800872), that regulate IL10 expression and they all are in strong LD. 39 Another probable explanation could be the suppression of IL10 production via activation of the STAT group of transcription regulation factors (repressors) by the IL10 gene variant. 40 IL6 rs1800795 SNP significantly affected the serum IL18 and IL6 levels as they were higher in the risk allele C carriers of this SNP. Since this is a promoter region polymorphism certain researchers suggest that it might directly affect at the transcription regulation factors (activators) leading to altered production of IL6 10 or that it might be tagging a gene variant affecting the transcriptional regulation of IL18 production. 34 Some studies suggest that the IL6 rs1800795 SNP might be altering the methylation levels of the IL6 gene promoter. 41 Previous studies have shown that various inflammatory cytokines are regulated via epigenetic mechanisms in human cancers 42 43 however, till today, the information regarding the epigenetic mechanisms regulating cytokines in PCAD is scarce and needs due attention. The risk allele A carriers of TNFA rs1800629 did not have significantly higher levels of serum TNFA in patients with PCAD as compared with the non-carriers in our study. A probable reason for this is that a study demonstrates that three genetic variants in the gene promoter of TNFA gene act synergistically to determine the functioning of the TNFA gene. 44 On the other hand serum IL18, IL18:IL10 and TNFA:IL10 ratios were significantly higher in the G allele carriers of TNFA rs1800629 SNP. A probable reason for this is that a study demonstrates that three genetic variants in the gene promoter of TNFA gene act synergistically to determine the functioning of the TNFA gene. 44 Cytokine polymorphisms have been shown to influence transcription, translation and levels of proteins in the atherosclerotic plaque. 45 The serum cytokine levels did not vary significantly with respect to the genotypic distribution of the cytokine gene promoter SNPs in the disease free controls of our study.
Genome-wide association studies have collectively reported a total of 31 loci, associated with CAD risk at genome-wide significance ( p<5×10 −8 ). 46 However, variants at these loci account for <10% of the heritability of CAD. There is increasing evidence that the genetic architecture of common traits involves a large number of causative alleles with minimal effects. Addressing this will require the discovery of additional loci to identify the molecular pathways underlying the pathogenesis of CAD. The cytokine gene promoter SNPs in our study were selected after a thorough literature search and from extensive meta-analyses 18 47 which is considered to be the gold standard for SNP selection. 12 Recent genome wide association studies and meta-analyses have identified cytokine genes and their variants (IL-18, IL-10, IL-6 and TNFA) as the potential CAD risk loci some of which significantly affect the serum cytokine levels. 44 48 49 However, gene variants may actually be tagging the functional SNPs in the transcriptional regulatory regions or gene promoter region of inflammatory or immune biomarkers involved in the pathogenesis of multifactorial diseases. 50 The carriage of the risk alleles might further increase transcription activity enhancing the proinflammatory status. In future studies nearest gene annotation can be informative and useful to differentiate between the actual causal variant and the tagging SNP. The concept of shared polygenetic signals can form the basis of detection of new loci for CAD. 51 The limitation of the study is the relatively small sample size and that most of the allele frequencies and effect sizes of the cytokine gene promoter SNPs available in literature have come from studies on individuals of Caucasian ethnicity and scarce allele frequency data is available on the South Asian population. Furthermore due to time and financial constraints all ethnic groups of Pakistan could not be studied but since the RAFs observed in the study were comparable with those observed in the Pakistan Risk of Myocardial Infarction Study (PROMIS). 52 Replication of the study with a larger sample size and by including other ethnic groups like Sindhis and Baluchis would help to get a broader perspective regarding the ethnic differences in the genotypic distribution and the RAFs of the selected cytokine SNPs in the Pakistani subjects.
CONCLUSIONS
The cytokine gene promoter SNPs (genotypic trait) have significant influence on the serum cytokine levels and the proinflammatory/anti-inflammatory cytokine imbalance ( phenotypic trait) which makes them important therapeutic and targets in patients with PCAD.
Main messages
▸ Genetic information has the potential to create a more personalised, prompt, early and accurate risk evaluation. ▸ Cytokine gene promoter single nucleotide polymorphisms (SNPs) are significantly associated with the serum proinflammatory/anti-inflammatory cytokine imbalance. ▸ Identifying the effect of genotypic distribution of cytokine SNPs on the phenotypic traits like serum cytokine levels will help to generate important insights into the heritability of complex traits and causal mechanisms involved in multifactorial diseases like premature coronary artery disease.
Current research questions
▸ Are the cytokine gene promoter single nucleotide polymorphisms (SNPs) leading to proinflammatory/ anti-inflammatory cytokine imbalance situated in the binding site of potential transcription factors? ▸ Do the cytokine gene promoter SNPs under consideration affect the expression of a reporter gene? ▸ Can new pathogenic mechanisms in premature coronary artery disease be unravelled by performing extensive gene annotation based on the results obtained in the current study?
